Your browser version may not work well with NCBI's Web applications. More information here...
1: Arthritis Res Ther. 2008;10(4):115. Epub 2008 Aug 12.Click here to read Click here to read Links

Suppression of bone morphogenetic protein inhibitors promotes osteogenic differentiation: therapeutic implications.

Heliotis M, Tsiridis E.

Bone morphogenetic proteins (BMPs) are expressed during osteogenesis and their action is regulated by corresponding BMP inhibitors. Chordin (a well recognized BMP inhibitor) and BMP-2 are expressed during osteogenic differentiation of human mesenchymal stem cells. Chordin inhibition induces human mesenchymal stem cell differentiation and reduces their proliferation by increasing BMP-2 bioavailability. The potential of suppressing BMP inhibitors is emerging as a biological therapeutic target in bone tissue engineering, because it results in an unopposed synergy between the various growth factors that are involved in osteogenesis, within their physiological milieu.

PMID: 18710600 [PubMed - indexed for MEDLINE]

PMCID: PMC2575635